doxylamine succinate and pyridoxine hydrochloride

FDA Drug Profile — Doxylamine Succinate and Pyridoxine Hydrochloride, BONJESTA, DICLEGIS

Drug Details

Generic Name
doxylamine succinate and pyridoxine hydrochloride
Brand Names
Doxylamine Succinate and Pyridoxine Hydrochloride, BONJESTA, DICLEGIS
Application Number
ANDA207825
Sponsor
Mylan Pharmaceuticals Inc.
NDC Codes
3
Dosage Forms
TABLET, DELAYED RELEASE, TABLET, EXTENDED RELEASE
Routes
ORAL
Active Ingredients
DOXYLAMINE SUCCINATE, PYRIDOXINE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE BONJESTA is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Limitations of Use BONJESTA has not been studied in women with hyperemesis gravidarum. BONJESTA is a fixed dose combination drug product of 20 mg doxylamine succinate, an antihistamine, and 20 mg pyridoxine hydrochloride, a Vitamin B 6 analog, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. ( 1 )